A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Tóm tắt
Visilizumab is a humanized anti-CD3 monoclonal antibody characterized by a mutated IgG2 isotype, lack of binding to Fcγ-receptors, and ability to induce apoptosis selectively in activated T cells. To test pharmacokinetics, safety, and immunosuppressive activity of visilizumab, 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in a phase 1 study. Six patients were given 7 doses of visilizumab (0.25 or 1.0 mg/m2) on days 1, 3, 5, 7, 9, 11, and 13. Because multiple doses of 1 mg/m2 caused delayed visilizumab accumulation and prolonged lymphopenia, the next 11 patients received a single dose of 3.0 mg/m2 on day 1. GVHD improved in all patients; 15 were evaluable through day 42. Multiple dosing resulted in 1 of 6 complete responses (CRs) and 5 partial responses (PRs), but all 6 patients died at a median of 87 days after starting visilizumab therapy. Single dosing resulted in 6 of 9 CRs, 3 PRs, and 7 of 11 patients surviving after 260 to 490 days (median, 359 days; P = .03). There were no allergic reactions and 3 grade 1 acute infusional toxicities. Plasma Epstein-Barr virus (EBV) DNA titers more than 1000 copies/mL and posttransplant lymphoproliferative disease (PTLD) developed in 2 of the first 7 patients. Based on rising EBV DNA titers, 5 of the next 10 patients were given the B cell–specific monoclonal antibody, rituximab. EBV DNA became undetectable and no overt PTLD developed. Visilizumab is well tolerated and has activity in advanced GVHD. A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy of visilizumab in GVHD.
Tài liệu tham khảo
Storb, 1986, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia., N Engl J Med., 314, 729, 10.1056/NEJM198603203141201
Nash, 1996, FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors., Blood., 88, 3634, 10.1182/blood.V88.9.3634.bloodjournal8893634
Martin, 1996, Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation., Blood., 88, 824, 10.1182/blood.V88.3.824.824
Martin, 1991, A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment., Blood., 77, 1821, 10.1182/blood.V77.8.1821.1821
Weisdorf, 1990, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome., Blood., 75, 1024, 10.1182/blood.V75.4.1024.1024
Khoury, 1999, Anti-thymocyte globulin (ATG) for steroid-resistant acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a costly therapy with limited benefits [abstract]., Blood., 94(suppl 1), 668a
Remberger, 2001, Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin., Clin Transplantation., 15, 147, 10.1034/j.1399-0012.2001.150301.x
Wells, 1999, Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance., Nat Med., 5, 1303, 10.1038/15260
Yu, 2000, Anti-CD3e F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens [abstract]., Blood., 96, 582a
Cole, 1999, HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro., Transplantation., 68, 563, 10.1097/00007890-199908270-00020
Cole, 1997, Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells., J Immunol., 159, 3613, 10.4049/jimmunol.159.7.3613
Hsu, 1999, A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees., Transplantation., 68, 545, 10.1097/00007890-199908270-00018
Parleviet, 1990, Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees., Transplantation., 50, 889, 10.1097/00007890-199011000-00030
Carpenter, 2000, Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells., J Immunol., 165, 6205, 10.4049/jimmunol.165.11.6205
Glucksberg, 1974, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors., Transplantation., 18, 295304, 10.1097/00007890-197410000-00001
Maloney, 1999, Preclinical and phase I and II trials of rituximab., Semin Oncol., 26, 74
Anasetti, 1992, Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody., Transplantation., 54, 844, 10.1097/00007890-199211000-00015
Zerr, 2001, Human herpesvirus 6 reactivation and encephalitis in allogeneic marrow transplant recipients., Clin Infect Dis., 33, 763, 10.1086/322642
Zerr, 2000, Sensitive method for detection of human herpesviruses 6 and 7 in saliva collected in field studies., J Clin Microbiol., 38, 1981, 10.1128/JCM.38.5.1981-1983.2000
Abrams, 2000, Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CLTA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells., J Exp Med., 192, 681, 10.1084/jem.192.5.681
Anasetti, 1990, Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen., J Exp Med., 172, 1691, 10.1084/jem.172.6.1691
Hansen, 1980, Monoclonal antibodies identifying a novel T-cell antigen and Ia antigens of human lymphocytes., Immunogenetics., 10, 247, 10.1007/BF01561573
Swinnen, 1999, Overview of postransplant B-cell lymphoproliferative disorders., Semin Oncol., 26, 21
McCaul, 2000, Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin., J Hematother Stem Cell Res., 9, 367, 10.1089/15258160050079470
Anasetti, 1994, Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor., Blood., 84, 1320, 10.1182/blood.V84.4.1320.1320
Przepiorka, 2000, Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute-graft-versus-host disease., Blood., 95, 83, 10.1182/blood.V95.1.83
Deeg, 2001, Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABX-CBL., Blood., 98, 2052, 10.1182/blood.V98.7.2052
Frangoul, 1998, Anti-CD3 antibody HuM291 induces peripheral T cell apoptosis in patients with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation., Blood., 92, 448a
Press, 1987, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas., Blood., 69, 584, 10.1182/blood.V69.2.584.584
Ledbetter, 1986, Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation., J Immunol., 136, 3945, 10.4049/jimmunol.136.11.3945
Anasetti, 1992, Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody., Transplantation., 54, 844, 10.1097/00007890-199211000-00015
Gratama, 1984, Treatment of acute-graft-versus-host-disease with monoclonal antibody OKT3: clinical results and effect on circulating T lymphocytes., Transplantation., 38, 469, 10.1097/00007890-198411000-00005
Curtis, 1999, Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study., Blood., 94, 2208
Cavazzana-Calvo, 1998, Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation., Br. J. Haematol., 103, 543, 10.1046/j.1365-2141.1998.00972.x
Hale, 1998, Risks of developing Epstein-Barr Virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants., Blood., 91, 3079, 10.1182/blood.V91.8.3079.3079_3079_3083
Hangretinger, 1999, Transplantation of megadoses of purified haploidentical stem cells., Ann N Y Acad Sci., 872, 351, 10.1111/j.1749-6632.1999.tb08479.x
Benkerrou, 1998, Anti-B cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome., Blood., 92, 3137, 10.1182/blood.V92.9.3137
Kuehnle, 2000, CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem-cell transplantation., Blood., 95, 1502, 10.1182/blood.V95.4.1502.004k40_1502_1505
Milpied, 2000, Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients., Ann Oncol., 11, S113, 10.1093/annonc/11.suppl_1.S113
Yamamoto, 1995, Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases., J Clin Microbiol., 33, 1765, 10.1128/JCM.33.7.1765-1768.1995
Gan, 1994, Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis., J Infect Dis., 170, 436, 10.1093/infdis/170.2.436
Niesters, 2000, Development of a real-time quantitative assay for detection of Epstein-Barr virus., J Clin Microbiol., 38, 712, 10.1128/JCM.38.2.712-715.2000